Research Alliance Corporation III has priced its initial public offering at $10.00 per Class A ordinary share, selling 7.5 million shares for gross proceeds of $75 million, the company said. The newly public vehicle started trading on the Nasdaq Capital Market under the ticker RACC on May 20, 2026.
The offering is scheduled to close on May 21, 2026, subject to the customary closing conditions that typically govern public offerings, the company noted. The SPAC is sponsored by an affiliate of RA Capital Management, L.P., and is managed by a leadership team that includes Chief Executive Officer Matthew Hammond and Chief Business Officer and Chief Operating Officer Henry Stusnick.
Management indicated the company intends to concentrate its search for a business combination on targets within healthcare and healthcare-related industries. Leerink Partners acted as the sole bookrunning manager for the offering, overseeing the syndication and execution of the IPO.
The financing attracted commitments from a range of institutional investors. The roster of participants included ADAR1 Capital, Affinity Asset Advisors, Balyasny Asset Management, Braidwell LP, BVF Partners, Cormorant Asset Management, Foresite Capital, Janus Henderson Investors, Perceptive Advisors, SilverArc Capital, Spruce Street Capital, TCGX, Trails Edge Capital Partners, and Venrock Healthcare Capital Partners.
According to the company statement, the U.S. Securities and Exchange Commission declared the registration statement for the securities effective on May 19, 2026. The SPAC structure and the sponsorship by an RA Capital affiliate, together with the list of participating institutional investors, frame the vehicle's initial capital base as it begins its search process in the targeted sectors.
Summary
- Research Alliance Corporation III priced 7.5 million Class A ordinary shares at $10.00 each, raising $75 million.
- The shares began trading on the Nasdaq Capital Market under the ticker RACC on May 20, 2026, with the offering expected to close on May 21, 2026, subject to customary closing conditions.
- The SPAC will focus its search on healthcare and healthcare-related industries and is sponsored by an affiliate of RA Capital Management, L.P., led by CEO Matthew Hammond and CBO/COO Henry Stusnick.
Key points
- Sector focus: The company is concentrating its acquisition search on healthcare and related fields, which will guide its deal pipeline and due diligence priorities.
- Institutional backing: A broad group of institutional investors participated in the financing, providing the SPAC with an initial capital base.
- Regulatory step: The SEC declared the registration statement effective on May 19, 2026, clearing a key regulatory milestone ahead of trading and the expected closing.
Risks and uncertainties
- The offering is expected to close on May 21, 2026, but remains subject to customary closing conditions; failure to meet those conditions could delay or prevent closing.
- Concentrating the search on healthcare and healthcare-related industries narrows the universe of potential targets and may limit options depending on market availability and valuation expectations.
- The SPAC's initial capital and success depend in part on the commitments and continued support of its institutional investors and sponsor, factors that could influence deal execution.